{"analyses":[{"ciLowerLimit":"0.14","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.27","estimateComment":"Stratified by Binet stage at Baseline.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.19","statisticalMethod":"Log Rank, Stratified"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.5","upperLimit":"33.0","value":"27.2"},{"groupId":"OG001","lowerLimit":"11.0","upperLimit":"12.1","value":"11.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by Independent Review Committee. Progressive disease required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \\>20 g/L or \\<10 g/dL or a decrease of platelet counts \\>50% or \\<100 x 10\\^9/L or by a decrease of neutrophil counts \\>50% or \\<1.0 x 10\\^9/L).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \\[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).","id":"OG000","title":"Obinutuzumab + Chlorambucil (GClb)"},{"description":"Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.","id":"OG001","title":"Chlorambucil (Clb)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population included all randomized participants. Patients without PFS events were censored.","reportingStatus":"POSTED","timeFrame":"Randomization to clinical cutoff date of 9 May 2013 (median observation 22.8 months)","title":"Progression Free Survival Based on Independent Review Committee (IRC) Data","type":"SECONDARY","unitOfMeasure":"Months"}